Matching trials
2,411 results
- CARTITUDE-1An independent statistical analysis of CARTITUDE-1, evaluating JNJ-68284528, a BCMA-directed CAR-T therapy in participants with relapsed or refractory multiple myeloma.
- Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors: Complete Statistical AnalysisIndependent statistical analysis of Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02717507).
- CATALYSTIndependent statistical analysis of A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- CBDIndependent statistical analysis of Cannabidiol Treatment in Patients With Early Psychosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02504151).
- CBGJ398XUS04Independent statistical analysis of BGJ398 for Patients With Tumors With FGFR Genetic Alterations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02160041).
- CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas: Complete Statistical AnalysisIndependent statistical analysis of CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00540579).
- CC-5013 (Lenalidomide) and Rituximab in Waldenstrom’s Macroglobulinemia: Complete Statistical AnalysisIndependent statistical analysis of CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00142168).
- CCBCRISIS04Independent statistical analysis of Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- CDP-Choline and Working Memory After TBI: A Neuroimaging Study: Complete Statistical AnalysisIndependent statistical analysis of CDP-Choline and Working Memory After TBI: A Neuroimaging Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00727246).
- Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery: Complete Statistical AnalysisIndependent statistical analysis of Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC: Complete Statistical AnalysisIndependent statistical analysis of Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04242173).
- CENTAURIndependent statistical analysis of Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cetuximab and Lenalidomide in Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab and Lenalidomide in Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01133665).
- Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA – NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC): primary endpoint results, effect estimate with confidence…
- CGDNIndependent statistical analysis of N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01265563).
- Chamomile for Chronic Primary Insomnia: Complete Statistical AnalysisIndependent statistical analysis of Chamomile for Chronic Primary Insomnia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01286324).
- CHAMPIndependent statistical analysis of Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02918292).
- CHAMPION 1Independent statistical analysis of A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CHANGEIndependent statistical analysis of "CHANGE COVID-19 Severity": primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04941703).
- Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir: Complete Statistical AnalysisIndependent statistical analysis of Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Chantix for Treating Cocaine Dependence: Complete Statistical AnalysisIndependent statistical analysis of Chantix for Treating Cocaine Dependence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00567008).
- CHASE 2Independent statistical analysis of A Study in Asthmatic Children (6 to
- CheckMate-568Independent statistical analysis of CheckMate-568 (NCT02659059), a phase 2 trial of nivolumab plus ipilimumab, with chemotherapy in Part 2, as first-line therapy for stage IV non-small cell lung cancer.
- Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease: Complete Statistical AnalysisIndependent statistical analysis of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia: Complete Statistical AnalysisIndependent statistical analysis of Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Chemoprevention of Gastric Carcinogenesis: Complete Statistical AnalysisIndependent statistical analysis of Chemoprevention of Gastric Carcinogenesis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02794428).
- Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00176800).
- Chemoradiation in Locally Advanced Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemoradiation in Locally Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00262951).
- Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with…
- Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01102231).
- Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer: primary endpoint results, effect estimate…
- Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors: primary endpoint results, effect estimate with confidence interval, sample-size…
- Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant: primary endpoint results,…
- Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501: Complete Statistical AnalysisIndependent statistical analysis of Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…